These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 2316280)
21. Protective efficacy of a recombinant vaccinia virus in vaccinia-immune mice. Andrew ME Immunol Cell Biol; 1989 Oct; 67 ( Pt 5)():339-41. PubMed ID: 2613281 [TBL] [Abstract][Full Text] [Related]
22. Pox viruses as eukaryotic cloning and expression vectors: future medical and veterinary vaccines. Taylor J; Paoletti E Prog Vet Microbiol Immunol; 1988; 4():197-217. PubMed ID: 3078866 [TBL] [Abstract][Full Text] [Related]
23. Effects of vaccinia virus-expressed interleukin 2 on the immune system of sublethally irradiated mice. Andrew ME; Karupiah G; Boyle DB; Blanden RV; Mullbacher A; Ramshaw IA; Coupar BE Microb Pathog; 1991 May; 10(5):363-71. PubMed ID: 1753876 [TBL] [Abstract][Full Text] [Related]
24. Increased attenuation but decreased immunogenicity by deletion of multiple vaccinia virus immunomodulators. Sumner RP; Ren H; Ferguson BJ; Smith GL Vaccine; 2016 Sep; 34(40):4827-34. PubMed ID: 27544585 [TBL] [Abstract][Full Text] [Related]
25. Induction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes. Legrand FA; Verardi PH; Jones LA; Chan KS; Peng Y; Yilma TD J Virol; 2004 Mar; 78(6):2770-9. PubMed ID: 14990697 [TBL] [Abstract][Full Text] [Related]
26. Use of lentivirus-like particles alone and in combination with live vaccinia-virus-based vaccines. Panicali DL; Mazzara G; Sullivan JL; Hesselton R; Shen L; Letvin N; Daniel M; Desrosiers R; Stott EJ AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1449. PubMed ID: 1466979 [No Abstract] [Full Text] [Related]
27. Characteristics of an attenuated vaccinia virus strain, LC16m0, and its recombinant virus vaccines. Sugimoto M; Yamanouchi K Vaccine; 1994 Jun; 12(8):675-81. PubMed ID: 8091843 [TBL] [Abstract][Full Text] [Related]
28. Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara. Ober BT; Brühl P; Schmidt M; Wieser V; Gritschenberger W; Coulibaly S; Savidis-Dacho H; Gerencer M; Falkner FG J Virol; 2002 Aug; 76(15):7713-23. PubMed ID: 12097585 [TBL] [Abstract][Full Text] [Related]
29. Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus. Morrison HG; Bauer SP; Lange JV; Esposito JJ; McCormick JB; Auperin DD Virology; 1989 Jul; 171(1):179-88. PubMed ID: 2741340 [TBL] [Abstract][Full Text] [Related]
30. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner. Gherardi MM; Ramirez JC; Rodríguez D; Rodríguez JR; Sano G; Zavala F; Esteban M J Immunol; 1999 Jun; 162(11):6724-33. PubMed ID: 10352291 [TBL] [Abstract][Full Text] [Related]
31. Comparison on virulence and immunogenicity of two recombinant vaccinia vaccines, Tian Tan and Guang9 strains, expressing the HIV-1 envelope gene. Zhu R; Huang W; Wang W; Liu Q; Nie J; Meng S; Yu Y; Wang Y PLoS One; 2012; 7(11):e48343. PubMed ID: 23139778 [TBL] [Abstract][Full Text] [Related]
32. Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination. Manning NM; Bachanek-Bankowska K; Mertens PPC; Castillo-Olivares J Vaccine; 2017 Oct; 35(44):6024-6029. PubMed ID: 28438410 [TBL] [Abstract][Full Text] [Related]
33. Characterization of an attenuated TE3L-deficient vaccinia virus Tian Tan strain. Wang Y; Kan S; Du S; Qi Y; Wang J; Liu L; Ji H; He D; Wu N; Li C; Chi B; Li X; Jin N Antiviral Res; 2012 Dec; 96(3):324-32. PubMed ID: 23084929 [TBL] [Abstract][Full Text] [Related]
34. Protective immunity against foot-and-mouth disease virus induced by a recombinant vaccinia virus. Berinstein A; Tami C; Taboga O; Smitsaart E; Carrillo E Vaccine; 2000 Apr; 18(21):2231-8. PubMed ID: 10717342 [TBL] [Abstract][Full Text] [Related]
35. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Crowe JE; Collins PL; London WT; Chanock RM; Murphy BR Vaccine; 1993 Nov; 11(14):1395-404. PubMed ID: 8310760 [TBL] [Abstract][Full Text] [Related]
37. B5-deficient vaccinia virus as a vaccine vector for the expression of a foreign antigen in vaccinia immune animals. Viner KM; Girgis N; Kwak H; Isaacs SN Virology; 2007 May; 361(2):356-63. PubMed ID: 17188733 [TBL] [Abstract][Full Text] [Related]
38. Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Taylor J; Weinberg R; Tartaglia J; Richardson C; Alkhatib G; Briedis D; Appel M; Norton E; Paoletti E Virology; 1992 Mar; 187(1):321-8. PubMed ID: 1736535 [TBL] [Abstract][Full Text] [Related]
39. Role of coexpression of IL-2 and herpes simplex virus proteins in recombinant vaccinia virus vectors on levels of induced immunity. Allen EM; Weir JP; Martin S; Mercadal C; Rouse BT Viral Immunol; 1990; 3(3):207-15. PubMed ID: 2175194 [TBL] [Abstract][Full Text] [Related]
40. Immunisation of cattle with a recombinant vaccinia vector expressing the haemagglutinin gene of rinderpest virus. Yamanouchi K; Inui K; Sugimoto M; Asano K; Nishimaki F; Kitching RP; Takamatsu H; Barrett T Vet Rec; 1993 Feb; 132(7):152-6. PubMed ID: 8456545 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]